Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 2
2010 1
2011 1
2012 1
2013 2
2014 2
2015 4
2016 4
2017 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

16 results
Results by year
Filters applied: . Clear all
Page 1
Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function.
Schmid DA, Irving MB, Posevitz V, Hebeisen M, Posevitz-Fejfar A, Sarria JC, Gomez-Eerland R, Thome M, Schumacher TN, Romero P, Speiser DE, Zoete V, Michielin O, Rufer N. Schmid DA, et al. Among authors: posevitz fejfar a. J Immunol. 2010 May 1;184(9):4936-46. doi: 10.4049/jimmunol.1000173. Epub 2010 Mar 29. J Immunol. 2010. PMID: 20351194 Free article.
Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation.
Gross CC, Schulte-Mecklenbeck A, Rünzi A, Kuhlmann T, Posevitz-Fejfár A, Schwab N, Schneider-Hohendorf T, Herich S, Held K, Konjević M, Hartwig M, Dornmair K, Hohlfeld R, Ziemssen T, Klotz L, Meuth SG, Wiendl H. Gross CC, et al. Among authors: posevitz fejfar a. Proc Natl Acad Sci U S A. 2016 May 24;113(21):E2973-82. doi: 10.1073/pnas.1524924113. Epub 2016 May 9. Proc Natl Acad Sci U S A. 2016. PMID: 27162345 Free PMC article.
PML risk stratification using anti-JCV antibody index and L-selectin.
Schwab N, Schneider-Hohendorf T, Pignolet B, Spadaro M, Görlich D, Meinl I, Windhagen S, Tackenberg B, Breuer J, Cantó E, Kümpfel T, Hohlfeld R, Siffrin V, Luessi F, Posevitz-Fejfár A, Montalban X, Meuth SG, Zipp F, Gold R, Du Pasquier RA, Kleinschnitz C, Jacobi A, Comabella M, Bertolotto A, Brassat D, Wiendl H. Schwab N, et al. Among authors: posevitz fejfar a. Mult Scler. 2016 Jul;22(8):1048-60. doi: 10.1177/1352458515607651. Epub 2015 Oct 2. Mult Scler. 2016. PMID: 26432858
Anti-JC-virus antibody prevalence in a German MS cohort.
Warnke C, Dehmel T, Posevitz-Fejfár A, Chan A, Berthele A, Schmidt S, Haas J, Kronsbein HC, Seitz F, Tackenberg B, Mäurer M, Gerbershagen K, Limmroth V, Adams O, Hartung HP, Gold R, Hemmer B, Wiendl H, Kieseier BC. Warnke C, et al. Among authors: posevitz fejfar a. Mult Scler. 2012 Jul;18(7):1054-5. doi: 10.1177/1352458511429955. Mult Scler. 2012. PMID: 22740609 No abstract available.
Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor).
Klotz L, Grützke B, Eveslage M, Deppe M, Gross CC, Kirstein L, Posevitz-Fejfar A, Schneider-Hohendorf T, Schwab N, Meuth SG, Wiendl H. Klotz L, et al. Among authors: posevitz fejfar a. BMC Neurol. 2015 Jun 23;15:96. doi: 10.1186/s12883-015-0354-9. BMC Neurol. 2015. PMID: 26099927 Free PMC article.
The proteolytic activity of the paracaspase MALT1 is key in T cell activation.
Rebeaud F, Hailfinger S, Posevitz-Fejfar A, Tapernoux M, Moser R, Rueda D, Gaide O, Guzzardi M, Iancu EM, Rufer N, Fasel N, Thome M. Rebeaud F, et al. Among authors: posevitz fejfar a. Nat Immunol. 2008 Mar;9(3):272-81. doi: 10.1038/ni1568. Epub 2008 Feb 10. Nat Immunol. 2008. PMID: 18264101
Fingolimod treatment promotes regulatory phenotype and function of B cells.
Grützke B, Hucke S, Gross CC, Herold MV, Posevitz-Fejfar A, Wildemann BT, Kieseier BC, Dehmel T, Wiendl H, Klotz L. Grützke B, et al. Among authors: posevitz fejfar a. Ann Clin Transl Neurol. 2015 Feb;2(2):119-30. doi: 10.1002/acn3.155. Epub 2015 Jan 16. Ann Clin Transl Neurol. 2015. PMID: 25750917 Free PMC article.
16 results